Alcon Labs Inc patents expiration
1. Eysuvis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11596599 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient
Dosage: SUSPENSION/DROPS;OPHTHALMIC
EYSUVIS family patents
2. Inveltys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
3. Pataday Once Daily Relief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
| US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
PATADAY ONCE DAILY RELIEF family patents
4. Simbrinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(6 years from now) | |
| US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(7 years from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic